论文部分内容阅读
目的观察卡培他滨(希罗达)对经蒽环类和(或)紫杉类药物治疗后复发或转移性乳腺癌的疗效分析和毒副反应。方法卡培他滨1250mg/m2,2次/d,餐后服用,连续服用2周,休息1周,至少2周期后评价疗效。结果全组60例无CR,PR16例(26.7%),SD32例(53.3%),PD12例(20%),总有效率26.7%,中位无进展生存时间9.8个月。常见副作用为手足综合征,皮肤色素沉着,腹泻,口腔发炎,恶心呕吐,白细胞及血小板减少,大部分为I-II度。结论应用卡培他滨单药治疗蒽环类和(或)紫杉类治疗后复发或转移性乳腺癌疗效确切,毒副反应轻,应用方便,值得临床推广使用。
Objective To observe the curative effect and toxicity of capecitabine (Xeloda) on recurrent or metastatic breast cancer after anthracycline and / or taxane treatment. Methods Capecitabine 1250mg / m2, 2 times / d, taken after meals, taking two consecutive weeks, rest for 1 week, at least 2 weeks after the evaluation of efficacy. Results There were 60 cases without CR, PR 16 cases (26.7%), SD 32 cases (53.3%) and PD 12 cases (20%) with a total effective rate of 26.7% and a median progression-free survival time of 9.8 months. Common side effects of hand-foot syndrome, skin pigmentation, diarrhea, oral inflammation, nausea, vomiting, white blood cells and thrombocytopenia, mostly I-II degrees. Conclusion The application of capecitabine monotherapy in the treatment of anthracycline and (or) taxane recurrence or metastatic breast cancer curative effect is exact, the side effects of light, easy to use, is worthy of clinical promotion and use.